Procainamide

Procainamide Monoclonal Antibodies

ORDERING INFORMATION

Catalog No. 16701	Clone No. PC10-138.2	MAb Subtype IgG3*	Size 100ug, 500ug	Library Pack No. 167101	100ug/clone All 7 clones
16704	PC12-416.1.1	IgG2b	100ug, 500ug
16705	PC12-424.5	IgG2b	100ug, 500ug
16706	PC10-131.1	IgG2b	100ug, 500ug
16707	PC10-183.2	IgG2a	100ug, 500ug
16708	PC10-242.6	IgG2b	100ug, 500ug
16709	PC10-253.2	IgG3*	100ug, 500ug

Format: Protein G-purified antibody in PBS, pH 7.4. *PEG-purified antibody in PBS, pH 7.4

BACKGROUND

Procainamide is an antiarrhythmic used to treat cardiac arrhythmias. It induces rapid block of the batrachotoxin (BTX)-activated sodium channels of the heart muscle and acts as antagonist to long gating closures. Procainamide is metabolized via different pathways. The most common one is the acetylation of procainamide to the less toxic N- acetylprocainamide. Procainamide was approved by the US FDA on June 2, 1950.

SPECIFICATION SUMMARY

Antigen: Procainamide conjugated to KLH by proprietary chemistry.
Host Species: Mouse
Specificity: These antibodies recognize procainamide and cross-react to different degrees with N-Acetylprocainamide:

% Cross-Reactivity with N-Acetylprocainamide
16701	8.4
16704	11.3
16705	10.6
16706	3.2
16707	0.4
16708	11.1
16709	2.2

APPLICATIONS

These antibodies have been qualified for use in ELISA to detect procainamide.

DILUTION INSTRUCTIONS

Dilute in PBS or medium that is identical to that used in the assay system.

STORAGE AND STABILITY

These antibodies are stable for at least one (1) year at -20°C to -70°C. Store product in appropriate aliquots to avoid multiple freeze-thaw cycles.

For in vitro investigational use only. Not intended for use in therapeutic or diagnostic procedures.

      Download PDF Data Sheet >